



Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update

October 24, 2019

CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both *in vivo* and *ex vivo*, will present third quarter 2019 results and operational highlights in a conference call on October 31, 2019 at 8 a.m. ET.

To join the call:

- U.S. callers should dial 888-208-1711 and use conference ID# 7693636, approximately five minutes before the call.
- International callers should dial +1 856-344-9299 and use conference ID# 7693636, approximately five minutes before the call.

A replay of the call will be available through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliadx.com, beginning on October 31, 2019 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients' diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliadx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investor Contact:

Lina Li
Associate Director, Investor Relations
+1 857-706-1612
lina.li@intelliadx.com

Media Contact:

Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliadx.com



Source: Intellia Therapeutics, Inc.